May 2, 2025 · Ruxience is a biosimilar to Rituxan and is used to treat certain leukemias and lymphomas and some non-cancer conditions, such as rheumatoid arthritis and polyangiitis.

See risks and benefits. Find information about RUXIENCE® (rituximab-pvvr) infusion, an FDA-approved biosimilar of RITUXAN® (rituximab), on the HCP site.

Also find the prescribing information, announcements, resources, and channels to connect with Pfizer Medical.

Aug 7, 2025 · RUXIENCE (rituximab-pvvr) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to pale brownish-yellow solution for intravenous infusion. RUXIENCE is …

Pfizer Oncology Together™ provides financial assistance resources to help patients access their prescribed Oncology medicines. for Healthcare professionals:

RUXIENCE is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.

May 19, 2024 · Learn about Ruxience (rituximab) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives.

It works by blocking a protein that causes cancer cells to grow and multiply. This helps to slow or stop the spread of cancer cells. It may also be used to treat autoimmune conditions, such as arthritis. It …

Ruxience is a a CD20-directed cytolytic antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia and granulomatosis with polyangiitis.

Apr 7, 2020 · Depending on the condition it is used to treat, Ruxience may be given on its own, or with chemotherapy (cancer medicines) or medicines used for inflammatory disorders (methotrexate or a …